

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : TD Cowen
Deal Size : $16.0 million
Deal Type : Public Offering
Atara Biotherapeutics Announces Pricing of $16 Million Offering
Details : The net procceds from the offering will be used to advance the development of Ebvallo (tabelecleucel), which is being evaluated for EBV-positive Post-Transplant Lymphoproliferative Disorders.
Product Name : Ebvallo
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
May 15, 2025
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : TD Cowen
Deal Size : $16.0 million
Deal Type : Public Offering

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO (tabelecleucel)
Details : Ebvallo (tabelecleucel) is an off-the-shelf allogeneic cell therapy composed of EBV specific cytotoxic T cell lymphocytes, indicated for EBV-associated post-transplant lymphoproliferative disease.
Product Name : Ebvallo
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 05, 2025
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atara Biotherapeutics Provides Update on Clinical Programs for EBVALLO™ and ATA3219
Details : FDA has placed a clinical hold on active IND applications of the EBVALLO (tabelecleucel) program as monotherapy treatment for adult and pediatric patients two years of age and older with EBV+ PTLD.
Product Name : Ebvallo
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
Details : Ebvallo (Tabelecleucel) is a gene therapy which is indicated as a monotherapy for the treatment of EBV-positive post-transplant lymphoproliferative disease.
Product Name : Ebvallo
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 16, 2025
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Priority Review for Tab-cel® in EBV-Positive Lymphoproliferative Disease
Details : Tab-Cel (Tabelecleucel) is a gene therapy which is indicated as a monotherapy for the treatment of EBV-positive post-transplant lymphoproliferative disease.
Product Name : Ebvallo
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 18, 2024
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atara Announces FDA Acceptance and Priority Review of Tabelecleucel for EBV Disease
Details : Tab-Cel (Tabelecleucel) is an allogeneic T-cell immunotherapy targetting EBV-infected cells, which is indicated for the treatment of EBV-positive post-transplant lymphoproliferative disease.
Product Name : Ebvallo
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 17, 2024
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Pierre Fabre
Deal Size : $667.0 million
Deal Type : Partnership
Atara Biotherapeutics Submits Tabelecleucel for EBV Positive Lymphoproliferative Disease
Details : Atara partners with Pierre Fabre for global commercialization of Tab-Cel (Tabelecleucel) for EBV-positive post-transplant lymphoproliferative disease.
Product Name : Ebvallo
Product Type : Cell & Gene Therapy
Upfront Cash : $27.0 million
May 20, 2024
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Pierre Fabre
Deal Size : $667.0 million
Deal Type : Partnership

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tabelecleucel
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Pierre Fabre
Deal Size : $640.0 million
Deal Type : Partnership
Details : Under the terms of the agreement, Pierre Fabre gains U.S. and remaining global commercial markets for tab-cel (tabelecleucel), an allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy.
Product Name : Ebvallo
Product Type : Cell & Gene Therapy
Upfront Cash : $30.0 million
November 01, 2023
Lead Product(s) : Tabelecleucel
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Pierre Fabre
Deal Size : $640.0 million
Deal Type : Partnership

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tabelecleucel
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : tab-cel (tabelecleucel) is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in an HLA-restricted manner.
Product Name : Ebvallo
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 18, 2023
Lead Product(s) : Tabelecleucel
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tabelecleucel
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Atara Biotherapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ebvallo™ (tabelecleucel) is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in an HLA-restricted manner.
Product Name : Ebvallo
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 08, 2023
Lead Product(s) : Tabelecleucel
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Atara Biotherapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable


 
															 Reset All
Reset All